Revolution Medicines, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Revolution Medicines (RVMD) received FDA approval for Rasonque, a RAS inhibitor for metastatic pancreatic cancer. The 30-day supply is priced at $39,800. Clinical trials showed improved survival rates compared to chemotherapy. The company faces challenges in payer negotiations and broader adoption.
Revolution Medicines' FDA-approved cancer drug, divarasib and razabi, targets RAS protein, previously deemed undruggable. CEO Mark Goldsmith bet the company on this target, leading to a successful Phase 3 trial. Michael Osterholm, 73, delayed retirement to address public health challenges, launching the Vaccine Integrity Project. David Baker, Nobel laureate, focuses on designing novel proteins and mentoring scientists.
Revolution Medicines Inc. (RVMD) reported that its experimental drug daraxonrasib shrank tumors in 33% of advanced lung cancer patients in a Phase 1/2 trial, with symptom improvements. The study, published in the New England Journal of Medicine, involved 136 patients with RAS gene mutations. The drug targets multiple RAS mutations and showed a median response duration of 11.5 months. Side effects were common, with rash, diarrhea, and nausea affecting many patients. The company is now conducting
Over the past 7 days, alphai's AI scored 11 news stories mentioning RVMD (Revolution Medicines, Inc.). Coverage has skewed bullish: 9 bullish, 1 neutral, and 1 bearish.
Recent RVMD coverage spans technology, regulation and insider activity.
In the last 30 days, RVMD insiders filed 31 SEC Form 4 transactions — no purchases and 31 sales ($41.3M). The most active reporter was GOLDSMITH MARK A, See Remarks, with 18 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Approval creates immediate commercial opportunity and pricing pressure; potential upside if payer coverage materializes.
Positive FDA approval likely to boost RVMD share price as the drug opens a new revenue stream.
Positive early‑stage data could boost RVMD share price as investors anticipate Phase 3 outcomes.
Positive early‑stage data may de‑risk the upcoming Phase 3 RASolve 301 trial and boost near‑term stock momentum.
Positive response and disease control rates suggest strong potential for Phase III, likely boosting investor sentiment.
alphai scores every news story that mentions RVMD with an AI model for sentiment and relevance, and aggregates insider trades from Revolution Medicines, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Revolution Medicines (RVMD) received FDA approval for Rasonque, a RAS inhibitor for metastatic pancreatic cancer. The 30-day supply is priced at $39,800. Clinical trials showed improved survival rates compared to chemotherapy. The company faces challenges in payer negotiations and broader adoption.
2 min readRevolution Medicines' FDA-approved cancer drug, divarasib and razabi, targets RAS protein, previously deemed undruggable. CEO Mark Goldsmith bet the company on this target, leading to a successful Phase 3 trial. Michael Osterholm, 73, delayed retirement to address public health challenges, launching the Vaccine Integrity Project. David Baker, Nobel laureate, focuses on designing novel proteins and mentoring scientists.
2 min readRevolution Medicines Inc. (RVMD) reported that its experimental drug daraxonrasib shrank tumors in 33% of advanced lung cancer patients in a Phase 1/2 trial, with symptom improvements. The study, published in the New England Journal of Medicine, involved 136 patients with RAS gene mutations. The drug targets multiple RAS mutations and showed a median response duration of 11.5 months. Side effects were common, with rash, diarrhea, and nausea affecting many patients. The company is now conducting
2 min readRevolution Medicines (RVMD) presented updated Phase 1/2 trial data for Rasonque in non-small cell lung cancer (NSCLC), showing a 42% overall response rate, 8.3-month median progression-free survival, and 16-month median overall survival. Truist Securities noted the results support RVMD's Phase 3 lung cancer study. Rasonque was recently FDA-approved for pancreatic cancer, with Phase 3 results expected in December 2027 for NSCLC.
2 min readRevolution Medicines (RVMD) published Phase I/II data in NEJM showing daraxonrasib's antitumor activity in RAS-mutant NSCLC. The study reported a 42% response rate and 8.3-month median progression-free survival. The company is advancing the drug in a Phase III trial. Daraxonrasib was recently approved for pancreatic cancer, marking the company's first commercial product.
2 min readRevolution Medicines (RVMD) announced the publication of Phase 1/2 trial results for RASONQUE in the New England Journal of Medicine. The data showed promising efficacy and safety in treating advanced RAS mutant NSCLC. The company has a market cap of $44.85 billion and is currently unprofitable, with a high Price-to-Sales ratio of 70.5x. Insider activity shows significant selling, while guru ownership trends are mixed.
3 min readRevolution Medicines (RVMD) reported Phase 1/2 trial results for RASONQUE (daraxonrasib) in metastatic non-small cell lung cancer (NSCLC) in the New England Journal of Medicine. In a subgroup of 38 patients, the drug achieved a 42% objective response rate, 89% disease control rate, 8.3-month median progression-free survival, and 16.0-month median overall survival. The company is conducting a Phase 3 trial (RASolve 301) comparing RASONQUE with docetaxel. RASONQUE is already FDA-approved for metas
2 min readKim Lorence H. sold 56,000 indirectly-held shares of Revolution Medicines, Inc. (RVMD) at an average of $203.24 ($200.56–$206.15, $11.38M total) across 7 trades on 2026-08-31 under a Rule 10b5-1 trading plan.
1 min readRevolution Medicines (RVMD) leased 672,000 sq ft for a new HQ in Redwood City, California, starting September 2027. The deal includes a $2.7M monthly base rent, $115.9M in tenant improvements, and a lease term through September 2042. Farallon Capital, a major shareholder, indirectly owns the landlords.
1 min readRevolution Medicines, Inc. (RVMD) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 27, 2026, Revolution Medicines, Inc. (the “Company”) agreed to lease the entirety of four buildings located at 1600, 1700, 1800 and 1900 Seaport Boulevard in Redwood City, California, comprising an aggregate of appro
1 min read
